Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

VisionWay Accessibility for People With Visual Impairments

Official title: VisionWay: Accessibility-Aware Path Selection for Wayfinding

Run by Ohio State University · NCT07713979 · Data updated 2026-11-12

A mobile tool called VisionWay tests whether a live outside map can help people who are blind or visually impaired choose safe walking paths to a chosen destination.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment100 (estimated)
SponsorOhio State University
Academic / other
Locations2 sites (Orono, Maine and 1 other locations)
StatusRecruiting
StartedFebruary 26, 2026
Main results expectedSeptember 1, 2027
Study endsSeptember 1, 2027
Registry record updatedJuly 20, 2026
Trial IDNCT07713979 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older with vision worse than 20/200, including those who are totally blind, who can consent and are willing to try a mobile, location-based guidance tool.

Probably not a fit

Participants who do not benefit may have routes where VisionWay cannot reliably identify hazards or who do not use the app as intended.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

VisionWay aims to provide a live, local outdoor walking map tailored for people with visual impairments to help decide which path to take before starting a walk. The approach builds on mobile sensing and AI to identify sidewalk features, crossings, obstacles, and hazards along multiple routes to a nearby destination. The study will test walking paths with participants who have severe vision loss, comparing routes with and without VisionWay guidance. It includes groups using no mobility aids, a cane, or a guide dog, to understand accessibility across different mobility configurations. Safety monitoring and expert oversight will ensure that trials are conducted under appropriate conditions.

Why it matters

Potential benefit: If successful, VisionWay could help PVI choose safer, more accessible routes before walking and reduce reliance on real-time guidance from remote operators.

How similar studies have gone: Previous work has explored remote guidance and environment-sensing aids for PVI, but comprehensive pre-walk route accessibility decision tools are still emerging.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* At least 18 years old
* Able to provide informed consent
* Vision worse than 20/200, encompassing PVI with severe and profound impairment as well as total blindness.

Group 1 Inclusion:

\- PVI meeting general inclusion criteria and without mobility aids

Group 2 Inclusion:

\- PVI meeting general inclusion criteria and who use a cane as a mobility aid

Group 3 Inclusion:

\- PVI meeting general inclusion criteria and who use guide dogs.

Exclusion Criteria:

* Conditions that prevent safe ambulation that include, but are not limited to, neuromuscular disorder, post-operative state (such as orthopedic surgeries or cardiac surgeries), balance issues, history of falls in the last 6 months, or at the discretion of the investigator.
* Use of walker or wheelchair

Where it's running

  • University of Maine
    Orono, Maine, United States
    Recruiting
  • Ohio State University
    Columbus, Ohio, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.